{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T16:33:15Z","timestamp":1757608395320,"version":"3.44.0"},"reference-count":33,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2022,12,6]]},"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1136\/ejhpharm-2022-003545","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:20:16Z","timestamp":1671542416000},"page":"301-306","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Is there a multinational consensus of tobramycin prescribing and monitoring for cystic fibrosis? Survey of current therapeutic drug monitoring practices in USA\/Canada, UK\/Ireland, and Australia\/New Zealand"],"prefix":"10.1136","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8929-4380","authenticated-orcid":false,"given":"Rebecca","family":"Larcombe","sequence":"first","affiliation":[{"name":"University of South Australia, Adelaide, South Australia, Australia"},{"name":"Flinders Medical Centre, Bedford Park, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kingsley","family":"Coulthard","sequence":"additional","affiliation":[{"name":"University of South Australia, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaughn","family":"Eaton","sequence":"additional","affiliation":[{"name":"Flinders Medical Centre, Bedford Park, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Tai","sequence":"additional","affiliation":[{"name":"Department Paediatrics, Women\u2019s and Children\u2019s Hospital, Adelaide, South Australia, Australia"},{"name":"University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Reuter","sequence":"additional","affiliation":[{"name":"University of South Australia, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ward","sequence":"additional","affiliation":[{"name":"University of South Australia, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"2025090221180207000_31.4.301.1","first-page":"CD006682","article-title":"Duration of intravenous antibiotic therapy in people with cystic fibrosis","volume":"9","author":"Plummer","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090221180207000_31.4.301.2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-013-9348-7"},{"key":"2025090221180207000_31.4.301.3","doi-asserted-by":"publisher","DOI":"10.4187\/aarc0443"},{"key":"2025090221180207000_31.4.301.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200812-1845PP"},{"key":"2025090221180207000_31.4.301.5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00576-6"},{"key":"2025090221180207000_31.4.301.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03045.x"},{"key":"2025090221180207000_31.4.301.7","doi-asserted-by":"publisher","DOI":"10.1002\/j.2055-2335.2011.tb00857.x"},{"key":"2025090221180207000_31.4.301.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2011.02452.x"},{"key":"2025090221180207000_31.4.301.9","doi-asserted-by":"publisher","DOI":"10.1002\/jppr.1145"},{"key":"2025090221180207000_31.4.301.10","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.02980"},{"key":"2025090221180207000_31.4.301.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17906-9"},{"key":"2025090221180207000_31.4.301.12","first-page":"239","article-title":"Tobramycin and beta-lactam antibiotic use in cystic fibrosis exacerbations: a pharmacist approach","volume":"21","author":"Zobell","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2025090221180207000_31.4.301.13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02654-15"},{"key":"2025090221180207000_31.4.301.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb05719.x"},{"key":"2025090221180207000_31.4.301.15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01131-16"},{"key":"2025090221180207000_31.4.301.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2006.05.015"},{"key":"2025090221180207000_31.4.301.17","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0211-9"},{"key":"2025090221180207000_31.4.301.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02114.x"},{"key":"2025090221180207000_31.4.301.19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jcf.2013.11.007","article-title":"Prescribing practices for intravenous aminoglycosides in UK cystic fibrosis clinics: a questionnaire survey","volume":"13","author":"Smyth","year":"2014","journal-title":"J Cyst Fibros"},{"key":"2025090221180207000_31.4.301.20","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-16.4.262"},{"key":"2025090221180207000_31.4.301.21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bcp.14372","article-title":"Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology","volume":"87","author":"Menz","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025090221180207000_31.4.301.22","unstructured":"Port CF Steering Committee . Port CF 2017: new Zealand CF data registry. Auckland, New Zealand; 2017. https:\/\/www.cfnz.org.nz\/assets\/Uploads\/cf3fb19c08\/Port-CF-2017-NZ-CF-Data-Registry-1-v2.1.pdf [Accessed 30 Oct 2022]."},{"key":"2025090221180207000_31.4.301.23","unstructured":"Registry ACFD . Australian cystic fibrosis data registry annual report 2019. Melbourne, Australia: Monash University, 2021."},{"key":"2025090221180207000_31.4.301.24","unstructured":"UK CF Registry Steering Committee . Cystic fibrosis: strength in numbers. UK; 2019. https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2020-12\/2019%20Registry%20Annual%20Data%20report_Sep%202020.pdf [Accessed 30 Oct 2022]."},{"key":"2025090221180207000_31.4.301.25","unstructured":"Ireland CFFo . Ireland2022 [Cystic Fibrosis Foundation of Ireland webpage], 2022. Available: https:\/\/www.cfireland.ie\/support-resources\/cf-centres [Accessed 30 Oct 2022]."},{"key":"2025090221180207000_31.4.301.26","unstructured":"Cystic Fibrosis Foundation Therapeutics Development N . 2019 Cystic Fibrosis Foundation patient registry highlights. Bethesda, Maryland, USA, 2020."},{"key":"2025090221180207000_31.4.301.27","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl328"},{"key":"2025090221180207000_31.4.301.28","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.1060"},{"key":"2025090221180207000_31.4.301.29","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1445-5994.2008.01787.x","article-title":"Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?","volume":"39","author":"Soulsby","year":"2009","journal-title":"Intern Med J"},{"key":"2025090221180207000_31.4.301.30","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.1.95"},{"key":"2025090221180207000_31.4.301.31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.3.623"},{"key":"2025090221180207000_31.4.301.32","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-019-4508-0","article-title":"Re-energising the way we manage change in healthcare: the case for soft systems methodology and its application to evidence-based practice","volume":"19","author":"Augustsson","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"2025090221180207000_31.4.301.33","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-7-50"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2022-003545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T04:18:12Z","timestamp":1756873092000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2022-003545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,6,21]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/ejhpharm-2022-003545"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2022-003545","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"type":"print","value":"2047-9956"},{"type":"electronic","value":"2047-9964"}],"subject":[],"published":{"date-parts":[[2022,12,20]]}}}